Meta-analysis of the adoption of omalizumab in the treatment of pediatric allergic diseases
Introduction: Allergic diseases are common chronic conditions in children, omalizumab has a wide range of adoptions in various diseases. A meta-analysis was implemented to demonstrate the efficacy of omalizumab in the therapy of pediatric allergic diseases. Materials and methods: English databases w...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-04-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844024053969 |
| _version_ | 1797200812289556480 |
|---|---|
| author | Baihua Xu Lingqun Tang Wenzhen Huang Shubin Xie Jiaxin Ye Guiping Luo |
| author_facet | Baihua Xu Lingqun Tang Wenzhen Huang Shubin Xie Jiaxin Ye Guiping Luo |
| author_sort | Baihua Xu |
| collection | DOAJ |
| description | Introduction: Allergic diseases are common chronic conditions in children, omalizumab has a wide range of adoptions in various diseases. A meta-analysis was implemented to demonstrate the efficacy of omalizumab in the therapy of pediatric allergic diseases. Materials and methods: English databases were searched. The search terms included “Omalizumab”, “Children”, “Allergic asthma”, and “Atopic dermatitis”. The literature was screened regarding inclusion and exclusion criteria, and data were extracted and analyzed using RevMan5.3. Results: a total of six suitable studies, comprising 2761 patients, were selected for inclusion. The meta-analysis results implied that at 24 weeks, OR for worsening of symptoms in children was 0.10 (95 % confidence interval [CI] 0.03–0.41), Z = 3.24, P = 0.001 (P < 0.05); at 52 weeks, OR was 0.27 (95 % CI 0.09–0.83), Z = 2.28, P = 0.02 (P < 0.05); and during treatment, OR for adverse events in children was 0.87 (95 % CI 0.60–1.29), Z = 0.68, P = 0.49 (P > 0.05). Conclusion: the study comprised six investigations that examined the effectiveness of omalizumab in treating pediatric allergic diseases. The findings demonstrated that, in comparison to standard treatment, omalizumab can greatly alleviate allergy-related clinical symptoms in children, slow down disease progression, and has a higher safety profile with fewer adverse reactions. These results have practical implications and highlight the potential value of omalizumab in pediatric allergy treatment. |
| first_indexed | 2024-04-24T07:37:36Z |
| format | Article |
| id | doaj.art-ab7c1d69ef624b85bd544691fd10102f |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-04-24T07:37:36Z |
| publishDate | 2024-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-ab7c1d69ef624b85bd544691fd10102f2024-04-20T04:17:35ZengElsevierHeliyon2405-84402024-04-01108e29365Meta-analysis of the adoption of omalizumab in the treatment of pediatric allergic diseasesBaihua Xu0Lingqun Tang1Wenzhen Huang2Shubin Xie3Jiaxin Ye4Guiping Luo5Department of Pediatric, Dongguan Hospital, Guangzhou University of Chinese Medicine, Dongguan, 523127, Guangdong Province, ChinaDepartment of Pediatric, Dongguan Hospital, Guangzhou University of Chinese Medicine, Dongguan, 523127, Guangdong Province, ChinaDepartment of Pediatric, Dongguan Hospital, Guangzhou University of Chinese Medicine, Dongguan, 523127, Guangdong Province, ChinaDepartment of Pediatric, Dongguan Hospital, Guangzhou University of Chinese Medicine, Dongguan, 523127, Guangdong Province, ChinaDepartment of Pediatric, Dongguan Hospital, Guangzhou University of Chinese Medicine, Dongguan, 523127, Guangdong Province, ChinaCorresponding author. Department of Pediatrics, Department of Inpatient, Dongguan Traditional Chinese Medicine Hospital, No. 3, Dongcheng Section, Songshanhu Avenue, Dongcheng Street, Dongguan City, Guangdong Province, China.; Department of Pediatric, Dongguan Hospital, Guangzhou University of Chinese Medicine, Dongguan, 523127, Guangdong Province, ChinaIntroduction: Allergic diseases are common chronic conditions in children, omalizumab has a wide range of adoptions in various diseases. A meta-analysis was implemented to demonstrate the efficacy of omalizumab in the therapy of pediatric allergic diseases. Materials and methods: English databases were searched. The search terms included “Omalizumab”, “Children”, “Allergic asthma”, and “Atopic dermatitis”. The literature was screened regarding inclusion and exclusion criteria, and data were extracted and analyzed using RevMan5.3. Results: a total of six suitable studies, comprising 2761 patients, were selected for inclusion. The meta-analysis results implied that at 24 weeks, OR for worsening of symptoms in children was 0.10 (95 % confidence interval [CI] 0.03–0.41), Z = 3.24, P = 0.001 (P < 0.05); at 52 weeks, OR was 0.27 (95 % CI 0.09–0.83), Z = 2.28, P = 0.02 (P < 0.05); and during treatment, OR for adverse events in children was 0.87 (95 % CI 0.60–1.29), Z = 0.68, P = 0.49 (P > 0.05). Conclusion: the study comprised six investigations that examined the effectiveness of omalizumab in treating pediatric allergic diseases. The findings demonstrated that, in comparison to standard treatment, omalizumab can greatly alleviate allergy-related clinical symptoms in children, slow down disease progression, and has a higher safety profile with fewer adverse reactions. These results have practical implications and highlight the potential value of omalizumab in pediatric allergy treatment.http://www.sciencedirect.com/science/article/pii/S2405844024053969OmalizumabChildrenAllergic asthmaAtopic dermatitisEfficacy |
| spellingShingle | Baihua Xu Lingqun Tang Wenzhen Huang Shubin Xie Jiaxin Ye Guiping Luo Meta-analysis of the adoption of omalizumab in the treatment of pediatric allergic diseases Heliyon Omalizumab Children Allergic asthma Atopic dermatitis Efficacy |
| title | Meta-analysis of the adoption of omalizumab in the treatment of pediatric allergic diseases |
| title_full | Meta-analysis of the adoption of omalizumab in the treatment of pediatric allergic diseases |
| title_fullStr | Meta-analysis of the adoption of omalizumab in the treatment of pediatric allergic diseases |
| title_full_unstemmed | Meta-analysis of the adoption of omalizumab in the treatment of pediatric allergic diseases |
| title_short | Meta-analysis of the adoption of omalizumab in the treatment of pediatric allergic diseases |
| title_sort | meta analysis of the adoption of omalizumab in the treatment of pediatric allergic diseases |
| topic | Omalizumab Children Allergic asthma Atopic dermatitis Efficacy |
| url | http://www.sciencedirect.com/science/article/pii/S2405844024053969 |
| work_keys_str_mv | AT baihuaxu metaanalysisoftheadoptionofomalizumabinthetreatmentofpediatricallergicdiseases AT lingquntang metaanalysisoftheadoptionofomalizumabinthetreatmentofpediatricallergicdiseases AT wenzhenhuang metaanalysisoftheadoptionofomalizumabinthetreatmentofpediatricallergicdiseases AT shubinxie metaanalysisoftheadoptionofomalizumabinthetreatmentofpediatricallergicdiseases AT jiaxinye metaanalysisoftheadoptionofomalizumabinthetreatmentofpediatricallergicdiseases AT guipingluo metaanalysisoftheadoptionofomalizumabinthetreatmentofpediatricallergicdiseases |